GE_HealthCare

Q3 2026
Speakers

Oct 28, 2026 · 53 min

PREPARED REMARKS · INFERREDKeys: / search · Space play · ←→ ±10s · [] sections

Prepared remarks

Speaker 0

Unverified voice label

Good day, and thank you for standing ?by. Welcome to the GE Healthcare Third Quarters 2026 Earnings Conference Call. ?At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. ?To ask a question during the session, you will need to press star 1 1 on your telephone. ?You will then hear an automated message advising your hand is raised.

To withdraw your question, please press star 1 1 again. Please be advised that today's conference is being recorded.
?I would now like to hand the conference over to your speaker today, Carolyn Borders, Head of Investor Relations. Please go ahead.

Passages & reports (11)
  • Good day, and thank you for standing
  • by.
  • Welcome to the GE Healthcare Third Quarters 2026 Earnings Conference Call.
  • At
  • this time, all participants are in a listen-only mode. After the speaker's presentation, t…
  • To
  • ask a question during the session, you will need to press star 1 1 on your telephone.
  • You
  • will then hear an automated message advising your hand is raised. To withdraw your questio…
  • I
  • would now like to hand the conference over to your speaker today, Carolyn Borders, Head of…

Speaker 1

Unverified voice label

Thanks, Operator. Good morning, and welcome to GE Healthcare's third quarter 2026 earnings call. I'm joined by our President and CEO, Peter Arduini, CFO Bill Grogan, and Controller and Chief Accounting Officer, George Newcomb. Our conference call remarks will include both GAAP and non GAP financial results. Reconciliations between GAAP and non-GAP measures can be found in today's press release and in the presentation slides available on our website.

During this call, we'll make forward-looking statements about our performance. These statements are based on how we see things today. As described in our SEC filings,
actual results may differ materially due to risks and uncertainties. With that, I'll hand the call over to Peter.

Passages & reports (3)
  • Thanks, Operator. Good morning, and welcome to GE Healthcare's third quarter 2026 earnings…
  • financial results. Reconciliations between GAAP and non-GAP measures can be found in today…
  • actual results may differ materially due to risks and uncertainties. With that, I'll hand …

Speaker 2

Unverified voice label

Thanks, Carolyn. Good morning, and thank you for joining us today. Before I review highlights from the quarter, I want to take a moment to welcome Bill. He brings tremendous experience and a strong track record, and I'm looking forward to partnering with him as we execute against our strategy and deliver on our priorities. Looking at our third quarter results on slide three, we delivered strong top line growth and margin expansion across all segments.

Broad based demand and advanced imaging solutions, and pharmaceutical diagnostics supported healthy orders, book to bill, and backlog. Heartbeat is strengthening how we run the company and
helping our teams deliver on commercial and operational simplification. A great example of performance driven by Heartbeat this quarter is patient care solutions. ?The team identified root causes of prior supply challenges and implemented standard work and daily management to drive ongoing improvements.

This drove backlog conversion and stronger operational performance. Taken together, momentum in our business has enabled us to raise our full year 2026 guidance, which Bill
will cover later in the call. Turning to slide four, let's look at how we're advancing our growth strategy. We reached key regulatory milestones in the quarter on two imaging platforms with market differentiating features. We receive CE marking for Photonova Spectra, our photon counting CT system, and Star Guide GX, our spec CT system, is pending FDA clearance.

This broadens our ability to commercialize in more markets. We also expanded our ultrasound platforms in cardiovascular, women's health, and general imaging with the launch of several new products to meet the growing
demand for non-invasive imaging. We continue to see general imaging ultrasound as an attractive market where we're investing for the long term. With growing demand, staffing constraints, and more distributed care, ultrasound's versatility across a broad range of exams is increasingly valuable.

Passages & reports (8)
  • Thanks, Carolyn. Good morning, and thank you for joining us today. Before I review highlig…
  • Looking at our third quarter results on slide three, we delivered strong top line growth a…
  • helping our teams deliver on commercial and operational simplification. A great example of…
  • The
  • team identified root causes of prior supply challenges and implemented standard work and d…
  • will cover later in the call. Turning to slide four, let's look at how we're advancing our…
  • CT system, and Star Guide GX, our spec CT system, is pending FDA clearance. This broadens …
  • demand for non-invasive imaging. We continue to see general imaging ultrasound as an attra…

PDX delivered another excellent quarter with growth in contrast media and radio pharmaceuticals, including proprietary tracers aligned to disease states. This was supported by momentum in precision medicine and growing demand for targeted diagnostics in oncology, cardiology, and neuro. Earlier this month, we announced our plans to acquire SOFI Biosciences. Upon close, this will establish a final mile footprint of U.S. PET radiopharmaceutical supply. It will also strengthen our pipeline through FAPE 74, a phase three PET tracer with the potential to help diagnose and treat a range of cancers and other diseases.

Heartbeat is driving improvement in execution across the company, keeping our teams focused on SQDCI, safety, quality, delivery, costs, and innovation in that order. In services, standardized digital support is helping our field engineers
resolve more issues on the first visit. We expect this to save approximately 10,000 hours of field time across CT, MR, and X-ray in the U.S. and get customers back up faster.

In AIS, stronger standard work and operating rigor around variable cost productivity delivered incremental cost reductions,
helping partially offset inflation. We recently entered multi year strategic agreements with several leading technology partners to secure memberships to strengthen the resiliency and predictability of our supply chain amid growing cross-industry demand for advanced computing components. We continue to pursue agreements to position us for the future. Lastly, before I hand the call over to Bill, today we announced that Jeanette Bankis, who leads our PCS business, will be leaving for a CEO role at a non competitive publicly traded company.

We thank her for her contributions and wish her the best.

Passages & reports (6)
  • PDX delivered another excellent quarter with growth in contrast media and radio pharmaceut…
  • we announced our plans to acquire SOFI Biosciences. Upon close, this will establish a fina…
  • of cancers and other diseases. Heartbeat is driving improvement in execution across the co…
  • resolve more issues on the first visit. We expect this to save approximately 10,000 hours …
  • helping partially offset inflation. We recently entered multi year strategic agreements wi…
  • agreements to position us for the future. Lastly, before I hand the call over to Bill, tod…

Leveraging our strong succession pipeline, I'm excited to announce that Neil Sandy, currently head of product strategy and management for PCS, will become the CEO of the business. I have tremendous confidence in Neil's capabilities given his current role and more than 30 years of experience in the industry. We remain focused on building on the progress the team achieved in the quarter, and we also are evaluating strategic options for this business.

With that, Bill will walk through the financials and guide. Bill? Thanks, Pete. Let me start by saying how excited I am to have joined GE Healthcare. I've

Passages & reports (2)
  • Leveraging our strong succession pipeline, I'm excited to announce that Neil Sandy, curren…
  • the progress the team achieved in the quarter, and we also are evaluating strategic option…

Speaker 3

Unverified voice label

been impressed by the talent and commitment of the team, ?and I look forward to helping

Passages & reports (3)
  • been impressed by the talent and commitment of the team,
  • and I look
  • forward to helping

Speaker 2

to build on the ?existing foundation ?as we execute on the significant

Passages & reports (5)
  • to build on the
  • existing
  • foundation
  • as
  • we execute on the significant

Speaker 3

opportunities ahead.

Passages & reports (1)
  • opportunities ahead.

Speaker unclear

?Now

Passages & reports (1)
  • Now

Speaker 2

let's turn to our third

Passages & reports (1)
  • let's turn to our third

Speaker 3

quarter financial results on slide five. We're pleased with our strong performance ?on both the top and bottom line and with growth ahead of expectations. Revenue of $5.5 billion increased 6.2% organically, with growth across all segments. ?On a reported basis, we had strong performance in both product and service revenues at 6.7% and 8.1% growth, respectively. Organic orders grew 4%. As a reminder, orders growth in the third quarter of last year was 5.7%, ?so we're growing mid-single digits on a strong baseline. ?

On
a trailing 12-month basis, organic orders growth was 4.6%. Book to bill was 1.03 times, and we exited the quarter with a backlog of $23.7 billion, up $2.5 billion, or 12% year over year. We made progress on margin expansion this quarter, delivering adjusted EBIT margin of 16.6%, up 180 basis points. I'll discuss the operational drivers in more detail on the next slide.

With our strong execution in the quarter, we delivered adjusted EPS of $1.34, up 25.1%. Lastly, our free cash flow was
$793 million, up $310 million versus the prior year. ?On slide six, we'll look at the drivers of margin expansion in the quarter. Our commercial execution helps us grow profitably as volume provided a healthy tailwind to margin. Additionally, the price and cost mitigation actions we've been taking across the business are starting to deliver a more meaningful benefit.

Tariff
expense was also lower than the prior ?year. Margin was negatively impacted by inflationary costs for memory chips as well as the impact of higher oil prices across our supply

Passages & reports (16)
  • quarter financial results on slide five. We're pleased with our strong performance
  • on
  • both the top and bottom line and with growth ahead of expectations. Revenue of $5.5 billio…
  • On
  • a reported basis, we had strong performance in both product and service revenues at 6.7% a…
  • so
  • we're growing mid-single digits on a strong baseline.
  • On
  • a trailing 12-month basis, organic orders growth was 4.6%. Book to bill was 1.03 times, an…
  • EBIT margin of 16.6%, up 180 basis points. I'll discuss the operational drivers in more de…
  • $793 million, up $310 million versus the prior year.
  • On
  • slide six, we'll look at the drivers of margin expansion in the quarter. Our commercial ex…
  • expense was also lower than the prior
  • year.
  • Margin was negatively impacted by inflationary costs for memory chips as well as the impac…

Speaker unclear

?chain.

Passages & reports (1)
  • chain.

Speaker 3

As we think about our margin expansion framework, it is built around two key areas underpinned by Heartbeat: commercial execution and operational simplification. Starting with commercial execution, our focus is on driving high quality, profitable growth. This includes capturing strategic pricing opportunities, standardizing our product launch playbook, and bringing new products to market at higher gross margins. ?As I've been coming up to speed on our business, a strong example is our vivid cardiovascular platform, where differentiated AI enabled capabilities supported premium pricing while a simplified design reduced manufacturing costs.

On the operational side, we are simplifying how we run the business and reducing
complexity across the organization. This includes advancing product platforming, optimizing our structural cost base, streamlining internal processes to eliminate rework, and the VCP examples Pete mentioned earlier. Together, these actions are helping us improve efficiency and create a more scalable operating model while supporting margin expansion. Let's move to our consolidated segment performance on slide seven.

Starting with advanced imaging solutions, organic revenue grew 4.5%, driven by strength in CT, cardiovascular and interventional solutions, and surgical
innovations. EBIT margin expanded 130 basis points year over year, driven by volume, reduced tariff expense, and price. ?This was partially offset by inflation. Demand for our cardiology solutions also increased, which was reflected in demand for our AI-enabled CT solutions, MR upgrades, and cardiovascular ultrasound.

Moving to pharmaceutical diagnostics, we delivered robust organic revenue
growth of 13.8% with contributions from contrast media and radio pharmaceutical products. Segment EBIT margin expanded 50 basis points to 29.9%, driven by volume and price, partially offset by planned investments in new products and our innovation pipeline.

Passages & reports (10)
  • As we think about our margin expansion framework, it is built around two key areas underpi…
  • opportunities, standardizing our product launch playbook, and bringing new products to mar…
  • As
  • I've been coming up to speed on our business, a strong example is our vivid cardiovascular…
  • complexity across the organization. This includes advancing product platforming, optimizin…
  • operating model while supporting margin expansion. Let's move to our consolidated segment …
  • innovations. EBIT margin expanded 130 basis points year over year, driven by volume, reduc…
  • This
  • was partially offset by inflation. Demand for our cardiology solutions also increased, whi…
  • growth of 13.8% with contributions from contrast media and radio pharmaceutical products. …

As mentioned, we also announced the planned acquisition of SOFI Biosciences. SOFI's revenue will add approximately one percent of total company revenue on an annualized basis. In the full year of ownership, revenue is expected to grow in low double digits with a creative adjusted EBIT margin and adjusted EPS. Patient care solutions delivered significant sequential improvement in the quarter. ?And year over year, organic revenue grew 8.8%, driven by improved operational performance, including better product fulfillment in monitoring solutions and maternal infant care.

Backlog continues to grow alongside revenue. Segment EBIT margin expanded 480 basis points year over year, primarily
driven by higher volume and cost productivity. Third quarter performance was better than expected with strong product fulfillment, driven by daily management and improved supplier and factory execution. We expect this to benefit us in the future. However, keep in mind that the fourth quarter of 2025 had an approximate $45 million revenue benefit from the release of a product hold.

Turning to cash performance on slide eight,
?we delivered free cash flow of $793 million in the third quarter. ?The year over year increase was supported by a reduction in net tariff impact, including lower payments as well as refunds in the quarter. Additionally, operational profitability and timing of collections help drive year-over-year improvements. We also increased our cash dividend by 14%, further enhancing returns to shareholders. ?

Now
let's turn to our outlook on slide nine. Our continued execution gives us increased confidence in our outlook. As a result, we are raising several of our full year 2026 metrics. ?We now expect organic revenue growth of approximately 4%, adjusted EBIT margin in the range of 15.5 to 15.7%, adjusted EPS in the range of $4.95 to $5.05 per share, and free cash flow in excess of $1.6 billion. ?

We
expect our adjusted effective tax rate to be in the range of 20 to 21% for the full year, and forward exchange tailwind to revenue of approximately 75 basis points. With that, I'll turn the call back to Pete. Thanks, Bill. I'd like to spend a few minutes

Passages & reports (17)
  • As mentioned, we also announced the planned acquisition of SOFI Biosciences. SOFI's revenu…
  • EPS. Patient care solutions delivered significant sequential improvement in the quarter.
  • And
  • year over year, organic revenue grew 8.8%, driven by improved operational performance, inc…
  • driven by higher volume and cost productivity. Third quarter performance was better than e…
  • approximate $45 million revenue benefit from the release of a product hold. Turning to cas…
  • we
  • delivered free cash flow of $793 million in the third quarter.
  • The
  • year over year increase was supported by a reduction in net tariff impact, including lower…
  • shareholders.
  • Now
  • let's turn to our outlook on slide nine. Our continued execution gives us increased confid…
  • We
  • now expect organic revenue growth of approximately 4%, adjusted EBIT margin in the range o…
  • We
  • expect our adjusted effective tax rate to be in the range of 20 to 21% for the full year, …

Speaker 2

highlighting PDX, a great example of how we're executing our D3 strategy, which brings together smart devices and drugs ?with a disease state focused NAI, enabling more precision care. PDX has delivered at least high single digits growth for five straight quarters. We're investing in strengthening our supply chain and manufacturing capabilities and expand where we can create value. As populations age and chronic disease rises, clinicians need imaging that answers sharper questions which treatment for which patient and when.

Managing the diseases often requires imaging at several points along the patient journey, from diagnosis to treatment to monitoring. Our agents are used in many of those imaging scans because
each scan uses a dose, PDX revenue is recurring and grows with patient volume. About three-quarters of the portfolio today is contrast media, where volumes grow with global procedure demand. We're also investing in what comes next with our MR manganese based contrast agent.

It has the
potential to address a nearly $1.2 billion market, ?and we're making good progress on our combined phase two and phase three international trial. ?The remaining balance of revenue contribution is from radio pharmaceuticals, one of our fastest growing markets. Here, PDX drugs and our AI enabled devices complement each ?other. Each new agent helps clinicians detect and monitor disease, which drives demand for imaging in our PET systems.

We're seeing that in our molecular imaging business, which grew strongly again this quarter. That combination is a differentiator for us as the only company with proprietary molecules and a large imaging
portfolio. We continue to see increased demand for our radio pharmaceutical portfolio, including Visimo and Seriana. And we're also seeing strong performance from established products like DATSCAN, our spec imaging agent for patients with suspected Parkinson's disease types.

Meanwhile,
FIRCATO is on track. We delivered approximately 680 doses for the week ending October 23rd, and we're seeing growing adoption across a broad base range of customer types. Those include the existing cardiac PET CT programs that have been partially or fully converted to FRICATO, as well as others that are converting from SPEC to PET. This adoption reflects FRICATO's diagnostic capabilities, longer half life, and flexible infrastructure.

To help expand the final mile distribution of these radio pharmaceuticals, we plan to acquire SOFI Biosciences.

Passages & reports (15)
  • highlighting PDX, a great example of how we're executing our D3 strategy, which brings tog…
  • with
  • a disease state focused NAI, enabling more precision care. PDX has delivered at least high…
  • rises, clinicians need imaging that answers sharper questions which treatment for which pa…
  • each scan uses a dose, PDX revenue is recurring and grows with patient volume. About three…
  • potential to address a nearly $1.2 billion market,
  • and
  • we're making good progress on our combined phase two and phase three international trial.
  • The
  • remaining balance of revenue contribution is from radio pharmaceuticals, one of our fastes…
  • other.
  • Each new agent helps clinicians detect and monitor disease, which drives demand for imagin…
  • portfolio. We continue to see increased demand for our radio pharmaceutical portfolio, inc…
  • FIRCATO is on track. We delivered approximately 680 doses for the week ending October 23rd…
  • converted to FRICATO, as well as others that are converting from SPEC to PET. This adoptio…

Pairing SOFI's network with our manufacturing scale ?will expand access and strengthen supply reliability, enabling us to directly manage a portion of our radio pharmaceutical manufacturer. It will also position us to advance the next generation of precision care, including PSMA, FAPI, and Theronostics, where the same molecules that diagnose a disease help guide targeted treatment. Simply put, PDX pairs resilient recurring revenue today with a pipeline and footprint to extend that growth.

In summary, we're pleased with third quarter results and importantly the strong contributions from our team.

Passages & reports (4)
  • Pairing SOFI's network with our manufacturing scale
  • will
  • expand access and strengthen supply reliability, enabling us to directly manage a portion …
  • diagnose a disease help guide targeted treatment. Simply put, PDX pairs resilient recurrin…

Heartbeat is helping us strengthen commercial execution and operational performance. Our focus on standard work and daily management has been critical in driving more consistent performance. We continue to advance our new wave of innovation, achieving key regulatory milestones in the quarter, and we're executing on our priorities, and our performance year-to-date gives us confidence in delivering on our commitments for patients, customers, and shareholders.

With that, we'll open up the call to questions.

Passages & reports (2)
  • Heartbeat is helping us strengthen commercial execution and operational performance. Our f…
  • priorities, and our performance year-to-date gives us confidence in delivering on our comm…

Speaker 1

Thank you, Peter. I'd like to ask participants to please limit yourself to one question and one follow up. Operator, can you please open the line?

Passages & reports (1)
  • Thank you, Peter. I'd like to ask participants to please limit yourself to one question an…

Speaker 0

Thank you. As a reminder, to ask a question, please press star 1 1 on your telephone and wait for your name to be announced. To withdraw your question, please press star 1 1 again. Please stand by while we compile the QA roster.

Passages & reports (1)
  • Thank you. As a reminder, to ask a question, please press star 1 1 on your telephone and w…

Questions & answers

Speaker 0

Our first question comes from the line of Travis Steed with Bank of America Securities. Your line is now open.

Passages & reports (1)
  • Our first question comes from the line of Travis Steed with Bank of America Securities. Yo…

Speaker 4

Unverified voice label

Hey, thanks for taking the question and Bill looking forward to working with you. Congrats on the new job at GE. I'd start with

Passages & reports (1)
  • Hey, thanks for taking the question and Bill looking forward to working with you. Congrats…

Speaker 3

the

Passages & reports (1)
  • the

Speaker 4

first question.

Passages & reports (1)
  • first question.

Speaker 2

Hey Travis, uh, thanks. Look, I mean, as you saw, and we you heard our comments, we're pleased with the corner results, the strong uh you know execution. I think you're starting to see some of the product differentiation coming through. But you know, relative to the capital budget market, ?um, you know, particular technologies like what we do in imaging, you know, from all of our survey data, discussion with CFOs, ranks at the top of the list.

I think you know we do a survey of kind of same-store sales with customers. And fundamentally, I would say the energy and positive focus on that
survey stays the same. I mean, it positions us well, I think, as we go into Q4 into next year. I know there's been some commentary around procedures pullback here and there in different areas. You know, we haven't seen that directly either in scan data or actually contrast use data at this point.

And, you know, indicators that would demonstrate slowdown or changes like that have to be multiple, multiple quarters. So I think we start seeing it coming through in our equipment. You know, one of the things about the imaging world is or other capital equipment, a lot of these are programs that are planned.

Passages & reports (5)
  • Hey Travis, uh, thanks. Look, I mean, as you saw, and we you heard our comments, we're ple…
  • um,
  • you know, particular technologies like what we do in imaging, you know, from all of our su…
  • survey stays the same. I mean, it positions us well, I think, as we go into Q4 into next y…
  • point. And, you know, indicators that would demonstrate slowdown or changes like that have…

You make a decision now for an installation that might be twelve, eighteen, twenty-four months out. And and I would say our you know funnel is as strong as it's ever been at this point in time. So we feel good about their trajectory, ?you know, as we come in the end of the year and as uh that ?you know converts into the beginning of twenty

Passages & reports (5)
  • You make a decision now for an installation that might be twelve, eighteen, twenty-four mo…
  • you
  • know, as we come in the end of the year and as uh that
  • you
  • know converts into the beginning of twenty

Speaker 4

Great. Thank you. And the follow-up question is more the backlog this quarter was down a little bit. Book the bill one point zero the lowest since the first quarter of twenty-four. Is that just lumpiness you're seeing or in quarter to quarter volatility? And you know, I guess part of it's probably fulfilling last quarter's strong orders as

Passages & reports (2)
  • Great. Thank you. And the follow-up question is more the backlog this quarter was down a l…
  • quarter's strong orders as

Speaker unclear

?well.

Passages & reports (1)
  • well.

Speaker 2

Yeah, no, I think that's it, Travis. I mean, I think is as you know, and and many that follow us, uh, from an order standpoint, you know, with big deals that we do that can be you know 100 million plus, you have some land in a given quarter, If they slide out by a week, it obviously creates a significant lumpiness. But we feel quite good about the orders.

Uh, you know, Bill had mentioned coming off of a strong year last year, both PDX and AIS uh did well. I I I would comment that our pipeline of opportunities remains strong, is up, um, which is you
know an underpinning of the resiliency that we we see out in the marketplace. So, ?you know, all of that I we feel quite good about it.

Um I think, you know, from a standpoint of of where we are with our capital equipment cycles and stuff, um, things are looking pretty good on the conversion.
?Uh as I look out into Q four, you know, our orders book looks uh a little bit better than we actually had in Q three.

Passages & reports (7)
  • Yeah, no, I think that's it, Travis. I mean, I think is as you know, and and many that fol…
  • a week, it obviously creates a significant lumpiness. But we feel quite good about the ord…
  • know an underpinning of the resiliency that we we see out in the marketplace. So,
  • you
  • know, all of that I we feel quite good about it. Um I think, you know, from a standpoint o…
  • Uh
  • as I look out into Q four, you know, our orders book looks uh a little bit better than we …

Speaker 4

Great. Thanks a lot.

Passages & reports (1)
  • Great. Thanks a lot.

Speaker 0

Thank you. Our next question comes from the line of VJ Kumar with Evercore ISI. Your line is now open.

Passages & reports (1)
  • Thank you. Our next question comes from the line of VJ Kumar with Evercore ISI. Your line …

Speaker 5

Unverified voice label

Uh good morning, um uh Pete and uh thanks for taking my question. Um and uh Bill uh congrats uh Andrew. Um I g I guess my first question, Pete, is on uh Fortato. Um your um ?you know you you gave the weekly dose assumption and the revenue run rate. How are you thinking about the path to 500 run rate exiting 28? How does Sophie help?

I think it makes the last mile connectivity, but how should we think about the ramp when you think uh uh Sophie is part of uh
part of uh G healthcare? Um does it improve your visibility to that half a billion um exit created in fiscal twenty eight?

Passages & reports (4)
  • Uh good morning, um uh Pete and uh thanks for taking my question. Um and uh Bill uh congra…
  • you know
  • you you gave the weekly dose assumption and the revenue run rate. How are you thinking abo…
  • part of uh G healthcare? Um does it improve your visibility to that half a billion um exit…

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 3

Vijay, look, I think with FRICADO, short answer is we feel very good about the half billion exiting 2028. I kind of, as I mentioned on the call, we're progressing as we expected. Feel good about the momentum and the weekly build. I think we're seeing broad based growth and interest. I think one of the interesting areas is as as I think we we know this started out as much as with heavy interest in pet users that were already in cardiovascular and that continues. ?

But
I think we're starting to also see now the broadening of spec users that are saying it's time to kind of start considering moving into the uh the pet world. And that's important because if you remember the long term opportunity is over eighty percent spec to pet. So both of those are growing. I think our funnels at this point in time are up significantly, which is what we look at on a forward metric about opportunities and what our conversion rate would ?be.

You know, one of the other key metrics I mentioned last quarter was the amount of customers that we converted. We converted about the same percentage of customers this quarter as we did last. And again, those will begin to build. It's that 60 day cycle of only a case or two until they get
reimbursement, and then that can ramp up into double digits.

So things look good. I think again, the positivity that we see from customers or hear from customers on all the attributes discussed image quality, dose management with larger patients, all those things are still playing out. And then just notably, I think
I mentioned in the comments the larger portfolio at radio pharma, meaning breast cancer imaging, imaging uh relative to other cancers and stuff continues to grow.

And that's important because it also means that department within an institution gets more focus. So there tends to be more dollars allocated in that area as well,
which we're beginning to

Passages & reports (10)
  • Vijay, look, I think with FRICADO, short answer is we feel very good about the half billio…
  • think one of the interesting areas is as as I think we we know this started out as much as…
  • But
  • I think we're starting to also see now the broadening of spec users that are saying it's t…
  • think our funnels at this point in time are up significantly, which is what we look at on …
  • be.
  • You know, one of the other key metrics I mentioned last quarter was the amount of customer…
  • reimbursement, and then that can ramp up into double digits. So things look good. I think …
  • I mentioned in the comments the larger portfolio at radio pharma, meaning breast cancer im…
  • which we're beginning to

Speaker unclear

?see.

Passages & reports (1)
  • see.

Speaker 5

That's helpful, Pete. And maybe my my second one on China in the region got back to growth. Has China bottomed up? Is is it back to growth? What is the normalized outlook, Pete? And um, you know, there are some questions coming on on maybe VVP imaging VBP in China. If there is one, uh could you elaborate on on uh what the impact

Passages & reports (2)
  • That's helpful, Pete. And maybe my my second one on China
  • in the region got back to growth. Has China bottomed up? Is is it back to growth? What is …

Speaker unclear

?is? Yeah,

Passages & reports (1)
  • is? Yeah,

Speaker 3

VJ, I I I don't know if I would give a full prediction as everything completely changed, but I can give you the play by play as we see it. And obviously our quarter, we've seen quarterly improvement within China. Um I think you'll see we had seven percent in the growth in the quarter, now albeit a majority of that was still driven by FX, it was positive with within the quarter.

And the market is definitely recovering. Um we're seeing, you know, activity improvement, which translates into consistency in tenders that are planned, tenders that are executed. We are actually seeing more
VBP. But I would say, you know, we've been changing our tactics, what configurations we offer, how we go to market that way, how we think about educating and interacting with a province or a smaller community.

And so I think our team that are led by Will has done a really nice job of
evolving the channel. That being said, I I think you know there's still lots of uh wood to chop, so to speak, here on advancing growth with within within China. But we were pleased with uh the results that the team put up here for for the quarter.

Passages & reports (4)
  • VJ, I I I don't know if I would give a full prediction as everything completely changed, b…
  • now albeit a majority of that was still driven by FX, it was positive with within the quar…
  • VBP. But I would say, you know, we've been changing our tactics, what configurations we of…
  • evolving the channel. That being said, I I think you know there's still lots of uh wood to…

Speaker 5

Understood. Thank

Passages & reports (1)
  • Understood. Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 0

Thank you. Our next question comes from the line of Matt Taylor with Jeffries. Your line is now open.

Passages & reports (1)
  • Thank you. Our next question comes from the line of Matt Taylor with Jeffries. Your line i…

Speaker 2

Hi, good morning. This is Matthew on for Matt Taylor. Thanks for taking our question and congrats on the quarter. I wanted

Passages & reports (1)
  • Hi, good morning. This is Matthew on for Matt Taylor. Thanks for taking our question and c…

Speaker 6

Unverified voice label

to ask about these multi-year agreements you have with technology partners and particularly on securing your memory trip supply. Could you possibly expand on how this helps you manage your costs going forward? Thanks.

Passages & reports (1)
  • to ask about these multi-year agreements you have with technology partners and particularl…

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 3

Matthew, I think uh you know we mentioned on the call that uh we've recently aligned that. I I think, look, pull the lens back big picture. Uh it's no secret that the growth of data centers and AI has has a big vortex effect on certain components around the industry. We think that's going to most likely exist for multiple years as this ramp up goes.

So we've taken an ecosystem approach to take a look at all of those things that could affect our business positively or negatively and reached out to the suppliers in the industry with what we believe is adequate lead time to secure first
supply and obviously manage pricing the best that we can. You know, at the end of the day, getting locked-in pricing agreements on some of these things isn't probably realistic, but being in a favored nation status that we're first in line to be able to take advantage of both supply and price is what we've uh been able to do.

So, you know, we feel quite good about uh where we are relative to some of the critical components like memory chips and stuff. But I think as uh others have talked about, over time this will evolve into other components and stuff, and and we're already focused on
that. So ?uh feel quite good about the work that uh Phil and the team have done broadly to be able to secure uh what we need to obviously deliver to our customers here not only in in the you know the rest of the year but into twenty seven

Passages & reports (7)
  • Matthew, I think uh you know we mentioned on the call that uh we've recently aligned that.…
  • to most likely exist for multiple years as this ramp up goes. So we've taken an ecosystem …
  • supply and obviously manage pricing the best that we can. You know, at the end of the day,…
  • we've uh been able to do. So, you know, we feel quite good about uh where we are relative …
  • that. So
  • uh
  • feel quite good about the work that uh Phil and the team have done broadly to be able to s…

Speaker 6

that's very helpful thank

Passages & reports (1)
  • that's very helpful thank

Speaker unclear

?you

Passages & reports (1)
  • you

Speaker 0

thank you our next question comes from the line of Robert Marcus with JP Morgan your line is now open

Passages & reports (1)
  • thank you our next question comes from the line of Robert Marcus with JP Morgan your line …

Speaker 2

hi good morning uh congrats on the quarter thanks for

Passages & reports (1)
  • hi good morning uh congrats on the quarter thanks for

Speaker unclear

?taking the questions uh two for me. First,

Passages & reports (1)
  • taking the questions uh two for me. First,

Speaker 7

Unverified voice label

can you talk to the guidance? It looks like it's factoring in a somewhat lower fourth quarter than the street was expecting. And any early thoughts on 27, both top and bottom line? You do have some tariff refunds to overcome, you know, strong order growth, uh trailing 12 months. Can that translate into accelerating sales growth for next year? ?And then I have a follow-up.

Thanks.

Passages & reports (4)
  • can you talk to the guidance? It looks like it's factoring in a somewhat lower fourth quar…
  • strong order growth, uh trailing 12 months. Can that translate into accelerating sales gro…
  • And
  • then I have a follow-up. Thanks.

Speaker 3

Hey, Robbie, uh, thanks for the question. I'll I'll start maybe just on the 27 piece and then toss over to Bill to

Passages & reports (1)
  • Hey, Robbie, uh, thanks for the question. I'll I'll start maybe just on the 27 piece and t…

Speaker 2

talk about implied Q4 the rest of the year.

Passages & reports (1)
  • talk about implied Q4 the rest of the year.

Speaker 3

I mean, I obviously we'll we'll give guide for 27 uh as we normally do out in in February. But I would say, look, there's a lot of moving parts. Um the momentum you can see this year on top line, we believe will continue. Um, both what you're seeing from an orders funnel, the translation of the backlog, how that's translating into revenue. So we feel good about the setup that we have moving into ?uh 27.

And on the bottom line, it's it's a similar story. I I think uh you know, the majority of this year hasn't been heavily impacted by our new products that actually have higher gross margins. We'll see a higher percentage of
?that. Um, we do have some scenarios on on tariffs and stuff, which we're in a little bit better position. But I I would caution the fact to say that ?you know there's no static tariff rates these days.

We have to see how some of that plays out. But in the world that we see today, we're in pretty good shape. Uh and then on variable cost productivity and price, we've been able to offset some of the major costs, not all of them, with
the combination of the two. And I would expect all that obviously to play through into 27. Maybe Bill, you can talk a little bit more about uh ?how we're thinking about the guide here for this year. ?

Yeah, no, thanks, Pete.
Exiting ?the third

Passages & reports (15)
  • I mean, I obviously we'll we'll give guide for 27 uh as we normally do out in in February.…
  • translation of the backlog, how that's translating into revenue. So we feel good about the…
  • uh
  • 27. And on the bottom line, it's it's a similar story. I I think uh you know, the majority…
  • that.
  • Um, we do have some scenarios on on tariffs and stuff, which we're in a little bit better …
  • you
  • know there's no static tariff rates these days. We have to see how some of that plays out.…
  • the combination of the two. And I would expect all that obviously to play through into 27.…
  • how
  • we're thinking about the guide here for this year.
  • Yeah, no, thanks, Pete.
  • Exiting
  • the
  • third

Speaker unclear

?quarter, I think we feel good about the

Passages & reports (1)
  • quarter, I think we feel good about the

Speaker 3

momentum. Right? We're building across the business. And heading into the fourth quarter, our backlog is up 12% versus the prior year. We had another solid quarter of top line growth from an expectations perspective with healthy margin and

Passages & reports (1)
  • momentum. Right? We're building across the business. And heading into the fourth quarter, …

Speaker 2

EPS

Passages & reports (1)
  • EPS

Speaker 3

expansion, right? With uh margins coming in

Passages & reports (1)
  • expansion, right? With uh margins coming in

Speaker 2

sequentially higher versus the third quarter. On the top line, though, AIS and PDX will drive growth for us in Q4. As I said in the prepared remarks, PCS's growth will be muted a bit due to the product hold catch up that we experienced last year, but they will grow

Passages & reports (1)
  • sequentially higher versus the third quarter. On the top line, though, AIS and PDX will dr…

Speaker 3

sequentially and have healthy year-over-year

Passages & reports (1)
  • sequentially and have healthy year-over-year

Speaker 2

margin expansion. ?So the

Passages & reports (3)
  • margin expansion.
  • So
  • the

Speaker 3

implied two

Passages & reports (1)
  • implied two

Speaker 2

four growth range of that three to four

Passages & reports (1)
  • four growth range of that three to four

Speaker 3

percent is really more around

Passages & reports (1)
  • percent is really more around

Speaker 2

the PCS

Passages & reports (1)
  • the PCS

Speaker 3

product

Passages & reports (1)
  • product

Speaker 2

hold comp versus any

Passages & reports (1)
  • hold comp versus any

Speaker 3

deceleration we

Passages & reports (1)
  • deceleration we

Speaker 2

see in the market. ?So I

Passages & reports (3)
  • see in the market.
  • So
  • I

Speaker 3

think the guide

Passages & reports (1)
  • think the guide

Speaker 2

appropriately reflects the strength we've seen while remaining mindful

Passages & reports (1)
  • appropriately reflects the strength we've seen while remaining mindful

Speaker 3

about the dynamic macro environment.

Passages & reports (1)
  • about the dynamic macro environment.

Speaker 7

Great. Maybe uh a quick follow-up here. PCS had been trending pretty negatively year to date, had a really strong quarter here. How do we think about you know the underlying versus any one-time items? And if it is all underlying strength, what what's driving that to to shift so positively? Thanks a

Passages & reports (2)
  • Great. Maybe uh a quick follow-up here. PCS had been trending pretty negatively year to da…
  • positively? Thanks a

Speaker unclear

?lot.

Passages & reports (1)
  • lot.

Speaker 3

Yeah, Robbie, I look, I think on PCS, uh, and I'd mentioned this, you know, in some previous calls, we we actually had some installations that had timing wise moved out more to the second half on monitoring projects. That's playing out as as we had thought. And so again, those aren't one-time things. We're going to see that continue to play out through into the beginning and on through into 27.

But one of the bigger challenges we had in in Q1, Q2 is just some of the supplier issues. And the team has really doubled down using our management system heartbeat. And again to really focus on getting
out with our suppliers where we've had supply constraints, how that ties out to demand capacity planning, both in our plants as well as with our customer sites.

Uh and I mentioned this focus on standard work and daily management. Think about it this way. I mean, this team has moved really from kind of
a monthly weekly cadence to a weekly daily cadence. And making sure that where there are any gaps relative to product capabilities, if there's any take uh issues relative to parts and components ?that they're addressed, and I think they've got the right rhythm in place.

And so we would expect that you're going to see continued improvements here from this point forward on PCS.

Passages & reports (6)
  • Yeah, Robbie, I look, I think on PCS, uh, and I'd mentioned this, you know, in some previo…
  • going to see that continue to play out through into the beginning and on through into 27. …
  • out with our suppliers where we've had supply constraints, how that ties out to demand cap…
  • a monthly weekly cadence to a weekly daily cadence. And making sure that where there are a…
  • that
  • they're addressed, and I think they've got the right rhythm in place. And so we would expe…

Speaker 7

Appreciate it. Thanks.

Passages & reports (1)
  • Appreciate it. Thanks.

Speaker 0

Thank you. Our next question comes from the line of Joanne Wanch with City. Your line is now open.

Passages & reports (1)
  • Thank you. Our next question comes from the line of Joanne Wanch with City. Your line is n…

Speaker unclear

?Good morning. Thank you so much for taking the

Passages & reports (1)
  • Good morning. Thank you so much for taking the

Speaker 1

question. ?Bill, welcome um

Passages & reports (3)
  • question.
  • Bill,
  • welcome um

Speaker unclear

?to

Passages & reports (1)
  • to

Speaker 2

the GE Healthcare team. I'm ?curious what

Passages & reports (3)
  • the GE Healthcare team. I'm
  • curious
  • what

Speaker unclear

?your first impressions are, um how you're thinking about um what you may implement or view differently for guidance. And

Passages & reports (1)
  • your first impressions are, um how you're thinking about um what you may implement or view…

Speaker 3

anything

Passages & reports (1)
  • anything

Speaker unclear

?you feel like sharing with us now that you're here?

Passages & reports (1)
  • you feel like sharing with us now that you're here?

Speaker 6

Yeah,

Passages & reports (1)
  • Yeah,

Speaker 2

no, I appreciate the question. So maybe maybe if I

Passages & reports (1)
  • no, I appreciate the question. So maybe maybe if I

Speaker 3

started out with just, hey, what are the things that attracted me to GE Healthcare along with ?what I'm

Passages & reports (3)
  • started out with just, hey, what are the things that attracted me to GE Healthcare along w…
  • what
  • I'm

Speaker 2

seeing?

Passages & reports (1)
  • seeing?

Speaker 3

Because I

Passages & reports (1)
  • Because I

Speaker 2

think they're fairly consistent. And there was a few things that I think were at the top of mind as one, I made the decision and two, my observations through the first six weeks. And first off, it starts with the purpose

Passages & reports (1)
  • think they're fairly consistent. And there was a few things that I think were at the top o…

Speaker 3

and culture, right? The purpose of creating a world where healthcare

Passages & reports (1)
  • and culture, right? The purpose of creating a world where healthcare

Speaker 2

has no limits is deeply embedded in how people make decisions here. Um, right, and there's that clear connection between our innovation and the impact we have for patients and customers. That was really important to be part of an organization that was mission focused. ?Um, right. I see a lot

Passages & reports (3)
  • has no limits is deeply embedded in how people make decisions here. Um, right, and there's…
  • Um,
  • right. I see a lot

Speaker 3

of opportunities to improve patient outcomes and expand access to care at a global scale, and that's incredible, incredibly

Passages & reports (1)
  • of opportunities to improve patient outcomes and expand access to care at a global scale, …

Speaker 2

compelling, and I think a huge opportunity for ?us. Um and I I I think the second thing is really around the growth opportunity. And we've highlighted some things within our prepared marks and some comments Pete

Passages & reports (3)
  • compelling, and I think a huge opportunity for
  • us.
  • Um and I I I think the second thing is really around the growth opportunity. And we've hig…

Speaker 3

has made, but I think we're at the forefront of healthcare innovation, right? We've got a strong technology portfolio

Passages & reports (1)
  • has made, but I think we're at the forefront of healthcare innovation, right? We've got a …

Speaker 2

and product pipeline. We've got this new phase of innovation that I think will be extremely impactful. Leveraging our growing capabilities in AI and digital, right? We have this huge installed

Passages & reports (1)
  • and product pipeline. We've got this new phase of innovation that I think will be extremel…

Speaker 3

install base and really deep relationships with our customers. I think bringing all those

Passages & reports (1)
  • install base and really deep relationships with our customers. I think bringing all those

Speaker 2

things together creates ?a compelling opportunity for long-term growth. Then lastly, I think it's ?really around a meaningful opportunity for me to help partner with the teams on driving operating

Passages & reports (5)
  • things together creates
  • a compelling
  • opportunity for long-term growth. Then lastly, I think it's
  • really
  • around a meaningful opportunity for me to help partner with the teams on driving operating

Speaker 3

performance through Heartbeat. I've seen strong business systems

Passages & reports (1)
  • performance through Heartbeat. I've seen strong business systems

Speaker 2

really have a

Passages & reports (1)
  • really have a

Speaker 3

big impact

Passages & reports (1)
  • big impact

Speaker 2

on results within organizations, ?you know,

Passages & reports (3)
  • on results within organizations,
  • you
  • know,

Speaker 3

where they have

Passages & reports (1)
  • where they have

Speaker 2

a desire to continuously

Passages & reports (1)
  • a desire to continuously

Speaker 3

improve

Passages & reports (1)
  • improve

Speaker 2

and a willingness to try new things to continue to deliver for their customers. That philosophically,

Passages & reports (1)
  • and a willingness to try new things to continue to deliver for their customers. That philo…

Speaker 3

but I've

Passages & reports (1)
  • but I've

Speaker 2

also seen it in ?practice. So the heartbeat methodology and the program that we have is increasingly embedded in how the teams operate here. And I think it's a further opportunity to continue to drive rigor and productivity and just general consistency along

Passages & reports (3)
  • also seen it in
  • practice.
  • So the heartbeat methodology and the program that we have is increasingly embedded in how …

Speaker 3

in a lot of things we do across the organization. ?And then maybe maybe last thing I

Passages & reports (3)
  • in a lot of things we do across the organization.
  • And
  • then maybe maybe last thing I

Speaker 2

I'd say is just the quality of the leadership team. Obviously, there's a significant appreciation to partner with folks like Pete and the balance of the management team that's really committed to executing for our customers and this great

Passages & reports (1)
  • I'd say is just the quality of the leadership team. Obviously, there's a significant appre…

Speaker 3

opportunity to drive long term shareholder value.

Passages & reports (1)
  • opportunity to drive long term shareholder value.

Speaker 0

Thank you. Our next question comes from the line of Lawrence Beagleson with Wells Fargo. Your line is now open.

Passages & reports (1)
  • Thank you. Our next question comes from the line of Lawrence Beagleson with Wells Fargo. Y…

Speaker unclear

?Uh

Passages & reports (1)
  • Uh

Speaker 7

good morning.

Passages & reports (1)
  • good morning.

Speaker 5

Thanks for taking ?the question. ?Uh Pete, uh two two for me. One on omnipay, it's it's an important product for you. Um you know um a competitor is guiding to fifty million plus ?in generic um um you know omnipace sales for next year. What share of that do you think comes from GE Healthcare? And how does generic omnipae impact your ability to grow PDX at a high single-digit rate, which is your midterm goal from a headline follow-up?

Passages & reports (7)
  • Thanks for taking
  • the
  • question.
  • Uh Pete,
  • uh two two for me. One on omnipay, it's it's an important product for you. Um you know um …
  • in
  • generic um um you know omnipace sales for next year. What share of that do you think comes…

Speaker 2

Yeah, Larry,

Passages & reports (1)
  • Yeah, Larry,

Speaker 3

look, thanks for the question.

Passages & reports (1)
  • look, thanks for the question.

Speaker 2

I'm not going to comment on maybe an entrance is what their proposal of

Passages & reports (1)
  • I'm not going to comment on maybe an entrance is what their proposal of

Speaker 3

what they may do or not do. But again, just to remind you and others is that, ?you know, this is a generic market already? It's been for you know over 15 plus years. There's been ?you know a half dozen plus players that have been come in and come out of the marketplace. And so again, it's not as a first proprietary product with its first generic change coming in.

That's not the dynamic we're we're dealing with here. Um we'll see how it ultimately plays out. This is a business that
you you need to actually have multiple SKUs, you need to have integration with injectors, all of those things that that play out in the marketplace. But I do think one of the most important parts are this market right now today, uh capacity is is maxed out.

So if you take a look at
demand, demand in many cases ?uh with supply is is right at an equilibrium where in some quarter, some months, we're almost maximizing that out. So I think an entrance that comes in that has some level of supply, it will be absorbed within the within the industry. You know, we're expecting this whole market to grow. We've mentioned this in previous sessions, almost 2x over the next, you know, seven to ten years.

So in a product like this, because it's interchangeable not only with us but with anybody else in the marketplace, it's going to fill the gap of the, you know, the opportunities that that exist. Um so you know, we we believe
they'll take a little bit of of business. I think it will be from the broader marketplace, not just from uh a GE Healthcare, but we feel quite good about our positioning.

And again,

Passages & reports (11)
  • what they may do or not do. But again, just to remind you and others is that,
  • you
  • know, this is a generic market already? It's been for you know over 15 plus years. There's…
  • you know
  • a half dozen plus players that have been come in and come out of the marketplace. And so a…
  • you you need to actually have multiple SKUs, you need to have integration with injectors, …
  • demand, demand in many cases
  • uh
  • with supply is is right at an equilibrium where in some quarter, some months, we're almost…
  • previous sessions, almost 2x over the next, you know, seven to ten years. So in a product …
  • they'll take a little bit of of business. I think it will be from the broader marketplace,…

Speaker 2

this isn't

Passages & reports (1)
  • this isn't

Speaker 3

the first time that we've faced

Passages & reports (1)
  • the first time that we've faced

Speaker 2

a generic uh player

Passages & reports (1)
  • a generic uh player

Speaker 3

coming into the marketplace.

Passages & reports (1)
  • coming into the marketplace.

Speaker unclear

?Yeah just uh wanted

Passages & reports (1)
  • Yeah just uh wanted

Speaker 5

to confirm PDX is still a high signal digit grower and um my f for my second question ?you know new CFO here uh hi Bill nice to meet you ?are are the midterm targets still intact and how should we think about the past your twenty twenty eight goals in twenty seven just asking Robbie's question a little bit differently thanks for

Passages & reports (5)
  • to confirm PDX is still a high signal digit grower and um my f for my second question
  • you
  • know new CFO here uh hi Bill nice to meet you
  • are
  • are the midterm targets still intact and how should we think about the past your twenty tw…

Speaker unclear

?taking the question.

Passages & reports (1)
  • taking the question.

Speaker 3

Yeah sure Larry I I mean, look, on on PDX, we feel quite good about its growth. You know, it's been growing double digits. Um, the the radio pharmaceutical side is growing significantly faster. That's going to continue based on all my previous comments, but we feel good about that. ?And look, on on medium term, I'll comment and then maybe have Bill make a few comments.

We continue to feel good about the medium uh term targets, full stop. I think on top line,
?you know, we're seeing the strong uh progress here. We've talked about being a mid single-digit grower. I think if you look at our trailing 12 months, we're roughly at five percent. That's mid-single digits. ?Um you saw it this quarter, Larry. And then on margin, ?you know, while the macroeconomic environment has created some headwinds for us, I think we've found space and and oxygen in what we've been able to do with new platforms, cost productivity, and also price.

So we feel good about both top and bottom line uh metrics in the midterm, which again we've defined by the
the twenty-eight numbers. So Bill, I don't know, maybe

Passages & reports (10)
  • Yeah sure Larry I I mean, look, on on PDX, we feel quite good about its growth. You know, …
  • And
  • look, on on medium term, I'll comment and then maybe have Bill make a few comments. We con…
  • you
  • know, we're seeing the strong uh progress here. We've talked about being a mid single-digi…
  • Um
  • you saw it this quarter, Larry. And then on margin,
  • you
  • know, while the macroeconomic environment has created some headwinds for us, I think we've…
  • the twenty-eight numbers. So Bill, I don't know, maybe

Speaker 2

you want

Passages & reports (1)
  • you want

Speaker 3

to add some comments. No,

Passages & reports (1)
  • to add some comments. No,

Speaker unclear

?I appreciate the question,

Passages & reports (1)
  • I appreciate the question,

Speaker 2

Larry.

Passages & reports (1)
  • Larry.

Speaker unclear

?So

Passages & reports (1)
  • So

Speaker 3

hey,

Passages & reports (1)
  • hey,

Speaker 2

so relatively early in my tenure, but

Passages & reports (1)
  • so relatively early in my tenure, but

Speaker unclear

?you

Passages & reports (1)
  • you

Speaker 3

know what I've seen so far gives me confidence in the direction we're headed. ?You know, to Pete's point on the growth side, I think the fundamental drivers of

Passages & reports (3)
  • know what I've seen so far gives me confidence in the direction we're headed.
  • You
  • know, to Pete's point on the growth side, I think the fundamental drivers of

Speaker 2

the market are strong, and

Passages & reports (1)
  • the market are strong, and

Speaker 3

we have this wave of new product introductions that

Passages & reports (1)
  • we have this wave of new product introductions that

Speaker 2

are

Passages & reports (1)
  • are

Speaker 3

differentiated

Passages & reports (1)
  • differentiated

Speaker 2

and

Passages & reports (1)
  • and

Speaker 3

customers

Passages & reports (1)
  • customers

Speaker 2

are really excited about. Um ?then on the margin side, right? I think there is fo uh the foundational elements there to progress on the uh margin aspirations that we have.

Passages & reports (3)
  • are really excited about. Um
  • then
  • on the margin side, right? I think there is fo uh the foundational elements there to progr…

Speaker unclear

?You

Passages & reports (1)
  • You

Speaker 3

know, I think there's a big part of just leveraging the strong top line growth with better product mix with these new product introductions we have and then building the productivity engine through heartbeat and the benefits that a strong operating system ?has and I'm looking forward to partnering

Passages & reports (3)
  • know, I think there's a big part of just leveraging the strong top line growth with better…
  • has
  • and I'm looking forward to partnering

Speaker unclear

?with the teams on

Passages & reports (1)
  • with the teams on

Speaker 2

that bringing some of the things that I I I of out of my tool set to ?help kind

Passages & reports (3)
  • that bringing some of the things that I I I of out of my tool set to
  • help
  • kind

Speaker 3

of uh

Passages & reports (1)
  • of uh

Speaker 2

enhance the capabilities. I know that's uh will be a huge driver of our gross margin improvements going forward.

Passages & reports (1)
  • enhance the capabilities. I know that's uh will be a huge driver of our gross margin impro…

Speaker 7

Thanks so much.

Passages & reports (1)
  • Thanks so much.

Speaker 0

Thank ?you. Our next question comes from the line of Ryan Zimmerman with US Bank Corp BTIG. Your line is now open.

Passages & reports (3)
  • Thank
  • you.
  • Our next question comes from the line of Ryan Zimmerman with US Bank Corp BTIG. Your line …

Speaker 2

Good morning. Can you hear me okay?

Passages & reports (1)
  • Good morning. Can you hear me okay?

Speaker 3

Again, Ryan, good morning.

Passages & reports (1)
  • Again, Ryan, good morning.

Speaker 2

Good morning. And uh Bill,

Passages & reports (1)
  • Good morning. And uh Bill,

Speaker unclear

?congrats. Uh it's good to have you in Chicago or it'd be all brewer's talk,

Passages & reports (1)
  • congrats. Uh it's good to have you in Chicago or it'd be all brewer's talk,

Speaker 3

I think, uh, on this call. So

Passages & reports (1)
  • I think, uh, on this call. So

Speaker 2

appreciate that. There's always next year.

Passages & reports (1)
  • appreciate that. There's always next year.

Speaker 3

But uh

Passages & reports (1)
  • But uh

Speaker 5

yeah, there's always

Passages & reports (1)
  • yeah, there's always

Speaker unclear

?next year for the Cubs. That's right. So just you know a couple questions for me. You know, first, there's been some dynamics in the uh imaging ultra in the general imaging ultrasound market. You know, Siemens pulling back a little bit, Phillips having some recalls. Pete, you made some comments about

Passages & reports (1)
  • next year for the Cubs. That's right. So just you know a couple questions for me. You know…

Speaker 5

ultrasound, your commitment to ?it. You know, remind us what the opportunity ?is for G Healthcare

Passages & reports (5)
  • ultrasound, your commitment to
  • it.
  • You know, remind us what the opportunity
  • is for
  • G Healthcare

Speaker unclear

?and do you see maybe

Passages & reports (1)
  • and do you see maybe

Speaker 5

some near-term benefit from the disruptions that are occurring in that segment of the market.

Passages & reports (1)
  • some near-term benefit from the disruptions that are occurring in that segment of the mark…

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 2

Ryan, look, yeah, and to your point, I mentioned this on the call.

Passages & reports (1)
  • Ryan, look, yeah, and to your point, I mentioned this on the call.

Speaker 3

General ultrasound, you know, imaging ultrasound is a super important market for us. It's an important market in the U.S., but it's actually a growing market around the world. Multi-purpose capabilities, Southeast Asia, Latin America. We see this in in Eastern

Passages & reports (1)
  • General ultrasound, you know, imaging ultrasound is a super important market for us. It's …

Speaker 2

Europe

Passages & reports (1)
  • Europe

Speaker 3

as well.

Passages & reports (1)
  • as well.

Speaker 2

It's

Passages & reports (1)
  • It's

Speaker 3

an

Passages & reports (1)
  • an

Speaker 2

entree into multiple

Passages & reports (1)
  • entree into multiple

Speaker 3

use that then moves into specialization. And actually having those products that way is critical. For us, this is a big business. In many cases, I understand while some people made decisions where they are, we're actually quite formidable in the space. It's a

Passages & reports (1)
  • use that then moves into specialization. And actually having those products that way is cr…

Speaker 2

critical

Passages & reports (1)
  • critical

Speaker 3

platform for us for us globally. And so, ?you know, as a result of that, we've continued to invest. When you hear the brand name Logic, which is the most well-known brand in general imaging around the world, it has been a you know significant winner, I'd say, in

Passages & reports (3)
  • platform for us for us globally. And so,
  • you
  • know, as a result of that, we've continued to invest. When you hear the brand name Logic, …

Speaker 2

the

Passages & reports (1)
  • the

Speaker 3

space. As we talk to customers, obviously, when you have a fleet of products, you want to be able to grow on it and build it over years. We think there will be some opportunities that that will you know play out for us ultimately. But this again is uh has been one of our strong suits for for many, many years. And the platforming work that Phil and the team have done in Ultrasound that leverages cost but productivity, this also will benefit across this platform.

So uh you know we think it's a great business, and you're gonna see us continue to invest and take advantage of what
market opportunities arise.

Passages & reports (3)
  • space. As we talk to customers, obviously, when you have a fleet of products, you want to …
  • strong suits for for many, many years. And the platforming work that Phil and the team hav…
  • market opportunities arise.

Speaker 5

Under

Passages & reports (1)
  • Under

Speaker unclear

?understood. And

Passages & reports (1)
  • understood. And

Speaker 3

and maybe you ?know, turning to

Passages & reports (3)
  • and maybe you
  • know,
  • turning to

Speaker 2

tariffs and margins, uh, I appreciate your comments. You know, as I think about next year's numbers, and again, appreciating that we're not going to get guidance, but the street is not assuming really a whole lot of margin expansion on the gross margin line for next year. ?Uh in fact, it's it's roughly

Passages & reports (3)
  • tariffs and margins, uh, I appreciate your comments. You know, as I think about next year'…
  • Uh
  • in fact, it's it's roughly

Speaker 5

flat. And so, you know, Bill, um it this isn't water filtration, but it still has the same, ?you know, impact on terror, you know, there is still tariffs to deal with. And so, ?you know, wondering if you could kind of elaborate on kind of what the dynamics are from a tariff standpoint, how you think about that impact for next year. You know, I know Robbie called out the tariff refund headwind, ?but but certainly there's still a tariff component to consider uh as we think about next year.

And and you know, frankly, can we see margins expand in 27?
?Uh appreciate it. Thank you. Yeah,

Passages & reports (9)
  • flat. And so, you know, Bill, um it this isn't water filtration, but it still has the same…
  • you
  • know, impact on terror, you know, there is still tariffs to deal with. And so,
  • you know,
  • wondering if you could kind of elaborate on kind of what the dynamics are from a tariff st…
  • but
  • but certainly there's still a tariff component to consider uh as we think about next year.…
  • Uh
  • appreciate it. Thank you. Yeah,

Speaker 2

yeah, Ryan, maybe I'll start and then maybe have George here just kind of reconcile what we said for

Passages & reports (1)
  • yeah, Ryan, maybe I'll start and then maybe have George here just kind of reconcile what w…

Speaker 3

this year. And then Bill, if you want to jump in, just commentary for next year, I think that would make some sense. ?But you know, look, uh obviously on the whole tariff piece on guide, as I as I mentioned, we'll talk more about that, you know, as we

Passages & reports (3)
  • this year. And then Bill, if you want to jump in, just commentary for next year, I think t…
  • But you
  • know, look, uh obviously on the whole tariff piece on guide, as I as I mentioned, we'll ta…

Speaker 2

get into

Passages & reports (1)
  • get into

Speaker 3

our 27 guide

Passages & reports (1)
  • our 27 guide

Speaker 2

window. But you know, we're we're

Passages & reports (1)
  • window. But you know, we're we're

Speaker 3

you know, regarding the biggest uncertain thing on tariffs out there is what happens with section 232. Um that's the you know the probably the biggest swing item out there. I'm assuming we'll probably hear more this year about how that plays out. We've been planning as though you know those will be increased rates at some level. Uh and so what does that mean?

We're preparing for price, we're preparing for cost productivity. Uh we've actually moved components as we've we've talked about. We've moved certain systems scenarios to countries to be able to offset some of that. So, you know, our focus is how things play out. We
want to make the right actions and take the right actions to still be able to have an accretive model.

I mean, that's part of our plan that we're going in there. George, you may want to comment just on what we stated here in the quarter and how to think about it. Yeah, sure.

Passages & reports (3)
  • you know, regarding the biggest uncertain thing on tariffs out there is what happens with …
  • at some level. Uh and so what does that mean? We're preparing for price, we're preparing f…
  • want to make the right actions and take the right actions to still be able to have an accr…

So, you know, in in the third quarter, our tariffs

Passages & reports (1)
  • So, you know, in in the third quarter, our tariffs

Speaker 2

are down year over year. You know, that's a result of a couple of things. One is the mitigation

Passages & reports (1)
  • are down year over year. You know, that's a result of a couple of things. One is the mitig…

Speaker unclear

?actions that the team has been

Passages & reports (1)
  • actions that the team has been

Speaker 4

driving. Secondly,

Passages & reports (1)
  • driving. Secondly,

Speaker unclear

?is just the lower overall rates that we're seeing. And then there was

Passages & reports (1)
  • is just the lower overall rates that we're seeing. And then there was

Speaker 6

about $4 million of AIPA tariff refunds related to 2026 that we recognized in the quarter. You know, consistent with how we treated this in 2Q26, we did adjust out about $9 million of refunds related to 2025. And Bill, do you want to comment on the Yeah? I mean, to your to ?your point about next year, obviously between tariffs and inflation, I think both are going to be persistent.

So So assuming kind of a steady state to where we're at at current levels,

Passages & reports (3)
  • about $4 million of AIPA tariff refunds related to 2026 that we recognized in the quarter.…
  • your point about
  • next year, obviously between tariffs and inflation, I think both are going to be persisten…

Speaker 2

I think we feel good about our ability to mitigate those actions through uh the team's ability to get increased pricing, continue to build our capabilities there, and then a significant amount of supply chain actions, you know, where we've done things internally and then partnered with key suppliers to minimize some of the volatility and reduce

Passages & reports (2)
  • I think we feel good about our ability to mitigate those actions through uh the team's abi…
  • and reduce

Speaker 3

our exposure. So obviously, we'll

Passages & reports (1)
  • our exposure. So obviously, we'll

Speaker 2

give you

Passages & reports (1)
  • give you

Speaker 3

more

Passages & reports (1)
  • more

Speaker 2

context when we come out in 2027, but overall ?uh understand you know it's a it's an issue, but confident in the team's ability to mitigate

Passages & reports (3)
  • context when we come out in 2027, but overall
  • uh
  • understand you know it's a it's an issue, but confident in the team's ability to mitigate

Speaker unclear

?it.

Passages & reports (1)
  • it.

Speaker 5

Thank you. Appreciate

Passages & reports (1)
  • Thank you. Appreciate

Speaker unclear

?it.

Passages & reports (1)
  • it.

Speaker 0

Thank you. Our next question comes from the line of Jason Bidnar with Piper Sandler. Your line is now open.

Passages & reports (1)
  • Thank you. Our next question comes from the line of Jason Bidnar with Piper Sandler. Your …

Speaker 4

Morning.

Passages & reports (1)
  • Morning.

Speaker unclear

?Thanks for

Passages & reports (1)
  • Thanks for

Speaker 5

taking the questions.

Passages & reports (1)
  • taking the questions.

Speaker 6

Um Pete, you and the team have been talking about realizing price to a greater degree. That's been a clear part of the strategy. ?Can you talk about where you're at in this journey of capturing price? Uh and are you finding even more headroom here real time on pricing as a result of passing through inflationary pressures that you're experiencing.

Passages & reports (3)
  • Um Pete, you and the team have been talking about realizing price to a greater degree. Tha…
  • Can
  • you talk about where you're at in this journey of capturing price? Uh and are you finding …

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 3

Jason. I I look, I mean, pricing is always tough in this business.

Passages & reports (1)
  • Jason. I I look, I mean, pricing is always tough in this business.

Speaker 2

Um,

Passages & reports (1)
  • Um,

Speaker 3

you

Passages & reports (1)
  • you

Speaker 2

know, mainly because obviously our customers run at very low margins.

Passages & reports (1)
  • know, mainly because obviously our customers run at very low margins.

Speaker 3

We're sensitive to that. We we try to make sure we look at all of the things around the edges first. And so obviously there's been some cases here where we've had to take actual list price or price increases on certain products. We we do that selectively. I think you know an important aspect of our whole NPI process is, ?you know, does a product bring really differentiated productivity and outcomes for a customer?

And when those match up,
?you know, paying more for price that you're going to see threefold in productivity changes in a world where you have employee shortages and in a world where you're really looking for productivity, that's really the matchup that we go for. And you know, we've got quite a few new products coming out that that hit that mark. Um, and so that's probably the top piece. ?

You
know, we focused our incentives with our sales force to make sure that we obviously get volume, but we get volume with the the right level of margins and price and and we've leaned in more to that uh most recently. Uh I I would also say just you know, thinking about configuration management is a big deal here. And I think you appreciate in capital equipment when you have many different options and stuff, getting the right configs and the right plays in there.

All of those things are are playing out. But again, you know, pricing in general in our world is uh a good pricing outcome is
a one to two percent window and and I think those are you know a lot of the efforts that have have been in place across the across the board.

Passages & reports (11)
  • We're sensitive to that. We we try to make sure we look at all of the things around the ed…
  • of our whole NPI process is,
  • you
  • know, does a product bring really differentiated productivity and outcomes for a customer?…
  • you
  • know, paying more for price that you're going to see threefold in productivity changes in …
  • that mark. Um, and so that's probably the top piece.
  • You
  • know, we focused our incentives with our sales force to make sure that we obviously get vo…
  • a big deal here. And I think you appreciate in capital equipment when you have many differ…
  • a one to two percent window and and I think those are you know a lot of the efforts that h…

Speaker 6

All right thank you. And then as just a follow up ?uh historically P I I think you've usually had a certain portion of the current and future quarter already spoken for with equipment installs and and install schedules. Just can you help with where you're at relative to historical historical averages both for the current fourth quarter and as you look at that installed schedule Zoo lineup for 2027?

Passages & reports (4)
  • All right thank you. And then as just a follow up
  • uh
  • historically P I I think you've usually had a certain portion of the current and future qu…
  • lineup for 2027?

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 3

I mean it starts with Jason having a record

Passages & reports (1)
  • I mean it starts with Jason having a record

Speaker 2

backlog. Uh you know, we we obviously ate in a little bit this quarter, but I think year to date we're up over a couple

Passages & reports (1)
  • backlog. Uh you know, we we obviously ate in a little bit this quarter, but I think year t…

Speaker 3

billion dollars. So I mean that's a tremendous uh asset for

Passages & reports (1)
  • billion dollars. So I mean that's a tremendous uh asset for

Speaker 2

us. Uh and so as

Passages & reports (1)
  • us. Uh and so as

Speaker 3

you look out

Passages & reports (1)
  • you look out

Speaker 2

into twenty

Passages & reports (1)
  • into twenty

Speaker 3

seven, even into

Passages & reports (1)
  • seven, even into

Speaker 2

twenty eight, we have delivery dates that

Passages & reports (1)
  • twenty eight, we have delivery dates that

Speaker 3

match up into that. ?You know, if I were to say Q four versus ?Q three, ?um, we're right in the same normal range that we would be, which is a high secured rate, meaning uh how much new business do you actually have to sell within the quarter to make your numbers? The vast, vast majority of it's already

Passages & reports (7)
  • match up into that.
  • You
  • know, if I were to say Q four versus
  • Q
  • three,
  • um,
  • we're right in the same normal range that we would be, which is a high secured rate, meani…

Speaker 2

on

Passages & reports (1)
  • on

Speaker 3

orders that we've taken. We've validated that the site is ready. We're

Passages & reports (1)
  • orders that we've taken. We've validated that the site is ready. We're

Speaker 2

working with the customer because they want the equipment. So it's very much in line

Passages & reports (1)
  • working with the customer because they want the equipment. So it's very much in line

Speaker 3

to what we had spoken about in Q three.

Passages & reports (1)
  • to what we had spoken about in Q three.

Speaker unclear

?All

Passages & reports (1)
  • All

Speaker 4

right,

Passages & reports (1)
  • right,

Speaker 6

very helpful. Thank

Passages & reports (1)
  • very helpful. Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 3

Thank you.

Passages & reports (1)
  • Thank you.

Speaker 0

Our next question comes from the line of Vic Chopra with BMO Capital Markets. Your line is now open.

Passages & reports (1)
  • Our next question comes from the line of Vic Chopra with BMO Capital Markets. Your line is…

Speaker 7

Oh hey, good morning. And uh

Passages & reports (1)
  • Oh hey, good morning. And uh

Speaker 5

thanks for taking the question. Uh Bill, welcome. Looking forward to working with you. And maybe just the first question on PCS, does that leadership change that you called out in the press release this morning, does that impact the timeline of the strategic review? And could it delay a decision? And then I had a quick follow up, please.

Passages & reports (2)
  • thanks for taking the question. Uh Bill, welcome. Looking forward to working with you. And…
  • a quick follow up, please.

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 3

no, thanks for the question. The short answer is no, it it does not. Um, look, we're

Passages & reports (1)
  • no, thanks for the question. The short answer is no, it it does not. Um, look, we're

Speaker 2

we're very happy

Passages & reports (1)
  • we're very happy

Speaker 3

actually for Jeanette

Passages & reports (1)
  • actually for Jeanette

Speaker 2

public company CEO jobs don't come around that often. ?Uh we're happy for it because it's not competitive with us. That uh makes us even more happy. But as I mentioned,

Passages & reports (3)
  • public company CEO jobs don't come around that often.
  • Uh
  • we're happy for it because it's not competitive with us. That uh makes us even more happy.…

Speaker 3

uh the the critical number two leader who's stepping into the role, Neil, knows this business extremely well, has been heavily involved in actually leading much of the work around the strategic assessment. So there's no impact relative to how we're thinking about things or or the impact of the recovery work. I mean Neil's been deep into that as

Passages & reports (2)
  • uh the the critical number two leader who's stepping into the role, Neil, knows this busin…
  • been deep into that as

Speaker unclear

?well.

Passages & reports (1)
  • well.

Speaker 2

Okay, great.

Passages & reports (1)
  • Okay, great.

Speaker 5

And then one on SOFI for me, uh I think they already manufacture uh Furcado. I'm just curious if owning SOFI speeds up the ramp. And can you disclose what percent of Furcado doses it supplies today? Thanks.

Passages & reports (1)
  • And then one on SOFI for me, uh I think they already manufacture uh Furcado. I'm just curi…

Speaker 3

Yeah I won't uh disclos uh d disclose for competitive reasons the the percentage, but I think you can appreciate we're pretty well distributed and spread out across multiple players is based on how how this works. ?But I it's a good question. I mean, I look, I I would just say part of the really exciting part about radio pharmaceuticals, there's many ways to play across the ecosystem and participate in revenue that's accretive and margins that are accretive to to GE healthcare.

Passages & reports (3)
  • Yeah I won't uh disclos uh d disclose for competitive reasons the the percentage, but I th…
  • But I
  • it's a good question. I mean, I look, I I would just say part of the really exciting part …

Speaker 2

And so, you know, I I

Passages & reports (1)
  • And so, you know, I I

Speaker 3

I would think less about Sophie as uh terms of the flourcato ramp, although it has the potential to benefit us, and more in the terms of this broader opportunity that that we see across the board. And again, having owning some of your manufacturing base in most scenarios is obviously a positive thing, particularly in radio pharmaceuticals. I we believe it's a very important aspect.

Think about the pipeline of the future of therapeutics as well as diagnostics. I believe there's over five 500 molecules in development as we speak. So that's an exciting opportunity. And you know, radio pharma is different than traditional
pharmaceuticals because these tracers have short half-lifes, meaning by the end of the day they're gone. And so you can't simply manufacture them centrally and hold inventory for extended periods.

You need to make it every day.

Passages & reports (3)
  • I would think less about Sophie as uh terms of the flourcato ramp, although it has the pot…
  • particularly in radio pharmaceuticals. I we believe it's a very important aspect. Think ab…
  • pharmaceuticals because these tracers have short half-lifes, meaning by the end of the day…

Speaker 2

So

Passages & reports (1)
  • So

Speaker 3

now

Passages & reports (1)
  • now

Speaker 2

we're

Passages & reports (1)
  • we're

Speaker 3

deeper into that process, which clearly helps us control more of our supply chain, but it also allows us for to participate. ?You know, we're going to be dependent and working with other CMOs for a very long period of time. This just gives us more, you know, ownership and and integration to play a significant role within that that channel. So we're excited about it.

Obviously, we need to get the deal closed, um, but uh that's
part of the strategy of why we uh we're

Passages & reports (4)
  • deeper into that process, which clearly helps us control more of our supply chain, but it …
  • You
  • know, we're going to be dependent and working with other CMOs for a very long period of ti…
  • part of the strategy of why we uh we're

Speaker 2

so interested in Sophie.

Passages & reports (1)
  • so interested in Sophie.

Speaker 0

Thank ?you. That concludes the question and answer session. Please proceed with any closing remarks.

Passages & reports (3)
  • Thank
  • you.
  • That concludes the question and answer session. Please proceed with any closing remarks.

Speaker 3

Yeah, thank you, operator, and uh thank all of our investors for your interest in GE Healthcare. We're looking forward to seeing many of you at the Radiological Society of North America in Chicago, known as RSNA. I think you're going to see lots of our new products ?in phase, so we're hoping that many of you can join us. Also, we're going to be showcasing significant amounts of new AI-enabled products integrated at a departmental level, integrated at a hospital level.

Many of the things that we've talked about, D3 in action, you're gonna see live actually on the floor. So we're super
excited about it. You know, this RSNA is a real pivotal window for us for many of those new products that will impact our growth profile and profit profile in twenty seven and twenty eight. So with that we'll conclude our call. Thank you very

Passages & reports (4)
  • Yeah, thank you, operator, and uh thank all of our investors for your interest in GE Healt…
  • in
  • phase, so we're hoping that many of you can join us. Also, we're going to be showcasing si…
  • excited about it. You know, this RSNA is a real pivotal window for us for many of those ne…

Speaker unclear

?much.

Passages & reports (1)
  • much.

Speaker 0

This concludes today's conference. Thank you for your participation. You may now disconnect.

Passages & reports (1)
  • This concludes today's conference. Thank you for your participation. You may now disconnec…
Source, accuracy & exportsMay contain errorsAccuracy unmeasured. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred.

Short unclear spans may appear inline between matching voice IDs. The ? marker retains unknown attribution; no voice identity is inferred for those words.

AI-generated transcript; names, numbers and wording may be inaccurate.

Speaker IDs are anonymous and local to this call. Section boundaries and timestamps are inferred.

1 words have zero-duration alignments. Use surrounding audio; no timing has been repaired.

The diarizer reached its eight-speaker limit; distinct voices may share an ID.

Zero-duration alignments: 1. Unassigned words: 305. No alignment has been repaired. Timestamps locate passages in the source recording; decimal positions do not establish word-level precision.

Official issuer source ↗ · Report an issue

Published transcript · Full recording available. Publication updated 2026-11-15T23:13:53.022Z.
Transcript version v1-d132fd5ac31b0587a330 · publication revision 1. Generated by AI; no listener-verified accuracy score is available.

Dotted spans marked ? have an unclear speaker. They remain unattributed even when shown inside a surrounding turn.

Copy or download
ReadableGrouped by speaker and paragraph with timestamps. Stored words unchanged.
As storedOne line per stored segment with its original speaker ID and start time. Exactly the stored words.
Official issuer source ↗Company overview ↗
TRANSCRIPT FEEDBACK

Report a passage

Your report is queued privately for review. It does not change this transcript automatically. Please avoid personal information.